The annual risks in the first year, assuming a baseline 10-year risk of fatal CVD of 5%, were:
for CHD, 0.68 with aspirin and 0.93 without aspirin;
for fatal CHD, 0.21 with aspirin and 0.24 without aspirin;
for stroke, 0.51 with aspirin and 0.50 without aspirin;
for fatal stroke, 0.09 with aspirin and 0.07 without aspirin;
for survival after a stroke, 0.43 with aspirin and 0.44 without aspirin;
for haemorrhagic stroke, 0.07 with aspirin and 0.06 without aspirin;
for ischaemic stroke, 0.36 with aspirin and 0.37 without aspirin;
for gastrointestinal bleeding, 0.31 with aspirin and 0.18 without aspirin.
The annual risks in the tenth year, assuming a baseline 10-year risk of fatal CVD of 5%, were:
for CHD, 1.69 with aspirin and 2.33 without aspirin;
for fatal CHD, 0.52 with aspirin and 0.60 without aspirin;
for stroke, 1.28 with aspirin and 1.26 without aspirin;
for fatal stroke, 0.22 with aspirin and 0.17 without aspirin;
for survival after a stroke, 1.06 with aspirin and 1.09 without aspirin;
for haemorrhagic stroke, 0.18 with aspirin and 0.16 without aspirin;
for ischaemic stroke, 0.89 with aspirin and 0.93 without aspirin;
for gastrointestinal bleeding, 0.31 with aspirin and 0.18 without aspirin.
The secondary prevention annual risks with aspirin were:
for nonfatal stroke, 0.58 to 5.39;
for nonfatal MI, 0.62 to 260;
for intracranial haemorrhage, 0.26;
for vascular death, 1.66 to 2.06;
for fatal and nonfatal gastrointestinal bleeds, 1.40.
The risks of dying from other causes were country-, age- and gender-specific.
The mean time trade-off score was 0.88 (95% confidence interval, CI: 0.84 to 0.93) for post-MI patients and 0.68 (95% CI: 0.53 to 0.83) for post-stroke patients.
If an acute event (MI or stroke) occurred, a utility of 0 was applied for 1 week.
Extracranial haemorrhage decreased utility for 2 weeks (utility of 0.5 was applied for 2 weeks).